Annual report pursuant to Section 13 and 15(d)

REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS (Tables)

v3.23.1
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS (Tables)
12 Months Ended
Dec. 31, 2022
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS  
Schedule of disaggregation of net revenues

​

​

​

​

​

​

​

​

​

    

Year Ended December 31, 

($ in thousands)

    

2022

    

2021

Qbrexza®

​

$

26,715

​

$

17,056

Accutane®

​

​

18,373

​

​

10,053

Targadox®

​

​

7,972

​

​

22,378

Amzeeq®

​

​

7,242

​

​

—

Ximino®

​

 

4,957

​

 

8,247

Zilxi®

​

 

2,273

​

 

—

Exelderm®

​

 

3,463

​

 

5,363

Other branded revenue

​

 

—

​

 

37

Total product revenues

​

$

70,995

​

$

63,134

​

Schedule of other revenue

​

​

​

​

​

​

​

​

​

    

Year Ended December 31,

($in thousands)

​

2022

    

2021

Other revenue

 

$

2,674

​

$

—

Total other revenue

​

$

2,674

​

$

—

​